Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.

摘要: PURPOSEThe clinical indications and economic consequences of human granulocyte colony-stimulating factor (G-CSF) prescription during small-cell lung cancer (SCLC) chemotherapy remain controversial. The aim this study, based on a Markov model, was to assess the impact routine G-CSF use in treatment SCLC costs patient comfort. models allow modeling chemotherapy, which risk febrile neutropenia (FN) is continuous over time may occur more than once.PATIENTS AND METHODSWe used model compare three strategies: dose reduction after FN nonuse ("never" strategy), secondary ("CSF if FN" strategy) primary ("systematic CSF" strategy). Model baseline probabilities were review medical records for all patients (n = 39) treated our unit 1993 (when not used) published reductions incidence obtained by using G-CSF. Two different types rewards ...